RecruitingPhase 1Phase 2NCT07349212
UKK-0018 is an Immunotherapeutic for Treatment of Peanut Allergies
A First-in-Human, Ascending Dose, Open-label, Multicenter Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of UKK-0018 in Peanut Allergic Individuals
Sponsor
Ukko Inc
Enrollment
40 participants
Start Date
Feb 18, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study will test a new investigational treatment called UKK-0018. UKK-0018 is an immunotherapeutic for the treatment of peanut allergies. The treatment is given by injection and is designed to train the immune system to tolerate peanut exposure over time.
Eligibility
Min Age: 18 YearsMax Age: 55 Years
Inclusion Criteria6
- Adults 18-55 years old
- documented history of physician-diagnosed peanut allergy
- positive skin prick test (SPT)
- screening DBPCFC peanut protein
- contraception use should be consistent with local regulations
- capable of providing signed written informed consent
Exclusion Criteria10
- asthma based on NHLBI
- uncontrolled cardiovascular disease
- chronic disease history
- exacerbation of dermatological conditions
- life threatening episodes of anaphylaxis
- active infections
- poor physical or blood chemistry
- immunodeficiency, bleeding disorders, malignancies
- hypersensitivities to epinephrine, inactive ingredients in therapy
- pregnant or breast feeding
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALUKK-0018
UKK0018 is an immunotherapeutic treatment of peanut allergies
Locations(5)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07349212